Literature DB >> 35804163

PET/MR of pediatric bone tumors: what the radiologist needs to know.

Jennifer Padwal1, Lucia Baratto1, Amit Chakraborty2, Kristina Hawk1, Sheri Spunt3, Raffi Avedian4, Heike E Daldrup-Link5,6,7.   

Abstract

Integrated 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG) positron emission tomography (PET)/magnetic resonance (MR) imaging can provide "one stop" local tumor and whole-body staging in one session, thereby streamlining imaging evaluations and avoiding duplicate anesthesia in young children. 18F-FDG PET/MR scans have the benefit of lower radiation, superior soft tissue contrast, and increased patient convenience compared to 18F-FDG PET/computerized tomography scans. This article reviews the 18F-FDG PET/MR imaging technique, reporting requirements, and imaging characteristics of the most common pediatric bone tumors, including osteosarcoma, Ewing sarcoma, primary bone lymphoma, bone and bone marrow metastases, and Langerhans cell histiocytosis.
© 2022. The Author(s), under exclusive licence to International Skeletal Society (ISS).

Entities:  

Keywords:  Bone sarcoma; Magnetic resonance; PET/MR; Pediatric cancer; Positron emission tomography

Year:  2022        PMID： 35804163     DOI： 10.1007/s00256-022-04113-6

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN： 0364-2348            Impact factor:   2.199


  63 in total

1.  Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know.

Authors:  Mizuki Nishino; Jyothi P Jagannathan; Nikhil H Ramaiya; Annick D Van den Abbeele
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

Review 2.  PET/MRI Hybrid Systems.

Authors:  Julia G Mannheim; Andreas M Schmid; Johannes Schwenck; Prateek Katiyar; Kristina Herfert; Bernd J Pichler; Jonathan A Disselhorst
Journal:  Semin Nucl Med       Date:  2018-04-10       Impact factor: 4.446

3.  Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.

Authors:  Maryam Aghighi; Justin Boe; Jarrett Rosenberg; Rie Von Eyben; Rakhee S Gawande; Philippe Petit; Tarsheen K Sethi; Jeremy Sharib; Neyssa M Marina; Steven G DuBois; Heike E Daldrup-Link
Journal:  Radiology       Date:  2016-03-16       Impact factor: 11.105

Review 4.  PET/MRI: Where might it replace PET/CT?

Authors:  Eric C Ehman; Geoffrey B Johnson; Javier E Villanueva-Meyer; Soonmee Cha; Andrew Palmera Leynes; Peder Eric Zufall Larson; Thomas A Hope
Journal:  J Magn Reson Imaging       Date:  2017-03-30       Impact factor: 4.813

Review 5.  Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma.

Authors:  Christian Buchbender; Till A Heusner; Thomas C Lauenstein; Andreas Bockisch; Gerald Antoch
Journal:  J Nucl Med       Date:  2012-07-10       Impact factor: 10.057

6.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

7.  Comparison of Standardized Uptake Values in Normal Structures Between PET/CT and PET/MRI in a Tertiary Pediatric Hospital: A Prospective Study.

Authors:  Karen Lyons; Victor Seghers; James I L Sorensen; Wei Zhang; Michael J Paldino; Rajesh Krishnamurthy; Eric M Rohren
Journal:  AJR Am J Roentgenol       Date:  2015-11       Impact factor: 3.959

Review 8.  Integrated whole body MR/PET: where are we?

Authors:  Hye Jin Yoo; Jae Sung Lee; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2015-01-09       Impact factor: 3.500

Review 9.  MR-PET of the body: Early experience and insights.

Authors:  Miguel Ramalho; Mamdoh AlObaidy; Onofrio A Catalano; Alexander R Guimaraes; Marco Salvatore; Richard C Semelka
Journal:  Eur J Radiol Open       Date:  2014-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.